Aprea Therapeutics

APRE

Market cap $11.5M

DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the closing of its previously announced oversubscribed private placement financing.

Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $30 million to the Company before deducting placement agent fees and other private placement expenses (the “Offering”).

Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancers Early clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitor Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea's development strategy of differentiated WEE1 inhibition with an improved therapeutic index A further update from the trial is expected in the second quarter of 2026 DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the confirmation of a partial response (PR) in its ongoing ACESOT-1051 trial evaluating APR-1051, a potent and selective WEE1 kinase inhibitor.

DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

Aprea Therapeutics (NASDAQ: APRE) shares are trading higher on Wednesday as the company announced additional preliminary data from its ongoing Phase 1 trial of APR-1051, a WEE1 kinase inhibitor.

Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Patient experienced only Grade 1 adverse events  Represents second patient with PR to harbor PPP2R1A mutation, supporting mechanistic thesis of targeting WEE1 for this patient population Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea's development strategy of differentiated WEE1 inhibition with an improved therapeutic index DOYLESTOWN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced additional preliminary data from the ongoing Phase 1 ACESOT-1051 trial evaluating its investigational WEE1 kinase inhibitor APR-1051.

DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced that Oren Gilad, Ph.D.

New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea's WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045.

Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051 Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051

Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patient The unconfirmed partial response (uPR) that was observed in the first scan has been achieved at the 150 mg dose, with 220 mg cohort currently enrolling in the ACESOT-1051 Potential dose-response trend observed with increasing single-agent activity across the 70 mg, 100 mg, and 150 mg cohorts Data provide early clinical proof-of-concept for single-agent APR-1051 in patients with advanced solid tumors DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the first unconfirmed partial response (uPR) observed in a patient enrolled in its ongoing Phase 1 ACESOT-1051 dose-escalation study (A Multi-Center Evaluation of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors).